| 14.16 -0.44 (-3.01%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.44 | 1-year : | 20.38 |
| Resists | First : | 14.93 | Second : | 17.44 |
| Pivot price | 13.1 |
|||
| Supports | First : | 12.8 | Second : | 11.47 |
| MAs | MA(5) : | 13.68 |
MA(20) : | 13.27 |
| MA(100) : | 15.25  |
MA(250) : | 16.29 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 81.6 |
D(3) : | 73.7 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 21.88 | Low : | 11.47 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SIBN ] has closed below upper band by 18.9%. Bollinger Bands are 21.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.6 - 14.67 | 14.67 - 14.73 |
| Low: | 13.71 - 13.79 | 13.79 - 13.85 |
| Close: | 14.04 - 14.17 | 14.17 - 14.27 |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Thu, 14 May 2026
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report - simplywall.st
Tue, 12 May 2026
SI-BONE, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SIBN) 2026-05-12 - Seeking Alpha
Tue, 12 May 2026
SI-BONE, Inc. (NASDAQ:SIBN) Q1 2026 Earnings Call Transcript - Insider Monkey
Tue, 12 May 2026
SI-BONE Inc (SIBN) Q1 2026 Earnings Call Highlights: Strong Reve - GuruFocus
Mon, 11 May 2026
Earnings call transcript: Si-Bone Q1 2026 beats EPS forecast, stock rises - Investing.com
Mon, 11 May 2026
SI-BONE Inc. (SIBN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 44 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 97.7 (%) |
| Shares Short | 4,630 (K) |
| Shares Short P.Month | 3,600 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | -9.5 % |
| Operating Margin | -4.4 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -11 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 3.61 |
| Sales Per Share | 4.54 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -32.19 |
| PEG Ratio | 0 |
| Price to Book value | 3.47 |
| Price to Sales | 3.11 |
| Price to Cash Flow | -928.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|